ZEVASKYN®
Not specified (Commercial Product)
Approved/CommercialActive Commercial Launch
Key Facts
Indication
Not specified (Commercial Product)
Phase
Approved/Commercial
Status
Active Commercial Launch
Company
About Abeona Therapeutics
Abeona Therapeutics is dedicated to delivering transformative cell and gene therapies for patients with severe rare diseases. The company has achieved a significant milestone with the commercial launch of ZEVASKYN® and maintains a diverse pipeline spanning preclinical to Phase 1/2 development, primarily targeting inherited retinal diseases and neurological conditions. Its strategy is supported by in-house manufacturing capabilities at The Elisa Linton Center for Rare Disease Therapies and key partnerships with Ultragenyx and Taysha Gene Therapies.
View full company profile